Navigation Links
Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
Date:5/6/2009

MONTREAL, May 6 /PRNewswire/ - Aegera Therapeutics is pleased to announce the initiation of a Phase 2a, proof-of-concept, clinical trial for AEG33773, a novel, orally bio-available small molecule therapeutic addressing the under-served market of painful diabetic neuropathy.

The Phase 2a study, entitled A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of AEG33773 versus Placebo in Patients with Painful Diabetic Peripheral Neuropathy will evaluate the efficacy, safety and tolerability of three dose levels of AEG33773 in diabetic patients suffering from significant neuropathic pain. This study is underway in Canada and Aegera will soon initiate trial sites in the Unites States, where the IND has recently cleared the FDA regulatory review process, and also in Europe, where the regulatory documents are now under review by the appropriate regulatory authorities.

"We are very excited about this first Phase 2 study for AEG33773 which has demonstrated robust preclinical in vivo data in multiple models of neuropathic and inflammatory pain. Furthermore, AEG33773 could have the potential to treat chronic pain conditions well beyond painful diabetic neuropathy." commented Dr. Jacques Jolivet, M.D., Senior Vice President Clinical Development of Aegera.

"With the successful conclusion of the Phase 1 safety studies for AEG33773 and the initiation of the first Phase 2a trial in diabetic patients suffering from significant neuropathic pain, we are now focused on successfully completing this trial while identifying an appropriate development partner; this will ensure that our novel agent is developed rapidly and effectively for its first indication while exploring additional indications so as to expand this franchise on a global basis." added Dr. Michael J. Berendt, Aegera's President and CEO.

About Aegera Therapeutics Inc. (www.aegera.com'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
2. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
3. Aegera Therapeutics welcomes two experienced executives to its board of directors
4. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
5. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
6. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
9. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2015)... April 02, 2015 One of ... to avoid false negative results. MultiGEN Diagnostics, LLC ... Laboratory Services, LLC (PCLS), has developed a novel ... false negatives, while at the same time maintains ... unique combination is expected to improve the quality ...
(Date:4/1/2015)... , April 1, 2015  Adaptive Biotechnologies ... The Lancet Oncology showing that ... company,s next-generation sequencing-based minimal residual disease (MRD) detection ... MRD test) accurately identifies patients with diffuse large ... relapse after initial treatment, usually several months before ...
(Date:4/1/2015)... Clara, CA (PRWEB) April 01, 2015 ... Force Microscopes (AFM) was selected to receive the ... The New Economy Magazine.    Park NX10 is the premium ... XY and Z scanner linearity, closed-loop detector noise, ... feature, SmartSca n, which allows images ...
(Date:4/1/2015)... 1, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") ... pleased to announce that Biohaven Pharmaceutical Holding Company ... entered into an agreement with inVentiv Health for ... with their lead compound (BHV-0223). ... of clinical stage neuroscience compounds targeting the glutamatergic ...
Breaking Biology Technology:MultiGEN Diagnostics, LLC Announces the Use of IC-Code™ Technology to Eliminate False Negatives in Molecular Diagnosis. 2Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 2Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 3Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 4Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 5Park Systems Awarded the New Economy Magazine “Best Analytic Instrumentation Company 2014” 2Portage's Biohaven Announces Agreement with inVentiv Health 2Portage's Biohaven Announces Agreement with inVentiv Health 3
... - Attendees at The 18th CPM Resource ... Era , The healthcare industry ... billions allotted for healthcare information technology transformation in,the American ... according to observations shared at the 18th CPM Resource ...
... In spite of continued growth in computational resources ... surrogate to physical reality still faces conceptual and ... of physical reality itself, under conditions of incomplete ... fluctuations. The quantification of this uncertainty has, in ...
... Acquisition LLC (the "Purchaser"), an affiliate of Biotechnology Value Fund ... purchase all of the outstanding shares of Avigen, Inc. (Nasdaq: ... today that it has extended the expiration date for the ... Friday, April 3, 2009. The tender offer was previously set ...
Cached Biology Technology:Experts at Healthcare Conference Support Investments in the Health of Work Culture and Care Processes, Not Just Technology 2Experts at Healthcare Conference Support Investments in the Health of Work Culture and Care Processes, Not Just Technology 3Experts at Healthcare Conference Support Investments in the Health of Work Culture and Care Processes, Not Just Technology 4Opportunities and challenges in uncertainty quantification for complex interacting systems 2BVF Acquisition LLC Extends Avigen Tender Offer to April 3, 2009 2BVF Acquisition LLC Extends Avigen Tender Offer to April 3, 2009 3
(Date:3/12/2015)... -- The mascots of the Atlantic Coast Conference spent ... Forest Baptist Medical Center. They stopped by as part ... Basketball Tournament. Young patients enjoyed bonding with their favorite ... Brenner Children,s Hospital is the pediatric arm ... hospital in northwest North Carolina ...
(Date:3/11/2015)... Mar. 11, 2015 Research and Markets ... "Access Control Market by Product, Application & By ... report to their offering. , This report ... reach $10.4 billion by 2020, with an estimated CAGR ... covers the products types such as contact cards & ...
(Date:3/10/2015)... Colo. , March 10, 2015 ... Flight "Personalized Medicine in Human Space ... and Thomas J. Goodwin , Ph.D. was recently ... of the past two years. Specifically, "Personalized ... most downloaded scientific papers published in 2013 and 2014 ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2
... 30,000 still images and video, as well as local ... Encyclopedia of Life via new tools that let the ... science collaboration of unprecedented scale. Experts and citizen ... encyclopedia, which dedicates a Web page to each known ...
... , , , ... biometric technology research and development firm, announced today that GHG ... provide their customers with M2SYS, Bio-SnapON(TM) biometric software solution. , ... biometric recognition capabilities to their web-based employee time tracking software, ...
... FORT WORTH, Texas, Aug. 4 Of the 600,000-800,000 people ... is estimated that by 2010, human trafficking will be the No. 1 ... Ph.D., professor and chairman of the department of forensic and investigative Genetics ... at the University of North Texas (UNT) Health Science ...
Cached Biology News:Cool new tools let public contribute to massive interactive online biodiversity encyclopedia 2Cool new tools let public contribute to massive interactive online biodiversity encyclopedia 3Cool new tools let public contribute to massive interactive online biodiversity encyclopedia 4Cool new tools let public contribute to massive interactive online biodiversity encyclopedia 5Cool new tools let public contribute to massive interactive online biodiversity encyclopedia 6Cool new tools let public contribute to massive interactive online biodiversity encyclopedia 7M2SYS Biometric Software Solution Selected By GHG Corporation 2DNA Helps Reunite Children With Their Families 2DNA Helps Reunite Children With Their Families 3
Goat polyclonal to Lipocalin 2...
Human GCP-2 is a member of the CXC family of chemokines. It also promotes neutrophil chemotaxis and deganulation. GF063 is an 8.0 kDa protein containing 73 amino acid residues....
... Hinge Region By immunoblotting the antibody reacts ... reacts with free MMP-2 or MMP-2 bound ... aqueous glycerol solution Solution in 0.01 ... 50% glycerol and 15 mM sodium azide. ...
human Exodus-2 Research Focus: cytokine/growth factor Storage Temperature: -20C Shipping Temperature: 4C...
Biology Products: